DNA (Cytosine-5-)-Methyltransferase 3 alpha (DNMT3A) ELISA Kits

CpG methylation is an epigenetic modification that is important for embryonic development, imprinting, and X-chromosome inactivation. Zusätzlich bieten wir Ihnen DNMT3A Antikörper (262) und DNMT3A Proteine (7) und viele weitere Produktgruppen zu diesem Protein an.

list all ELISA KIts Gen GeneID UniProt
DNMT3A 1788 Q9Y6K1
Anti-Maus DNMT3A DNMT3A 13435 O88508
DNMT3A 444984 Q1LZ53
Direkt bei antikoerper-online bestellen
  • +1 877 302 8632
  • +1 888 205 9894 (toll-free)
  • Online bestellen
  • orders@antikoerper-online.de

Top DNMT3A ELISA Kits auf antikoerper-online.de

Showing 2 out of 12 products:

Katalog Nr. Reaktivität Sensitivität Bereich Bilder Menge Anbieter Lieferzeit Preis Details
Human 0.061 ng/mL 0.15 ng/mL - 10 ng/mL 96 Tests Anmelden zum Anzeigen 13 bis 16 Tage
$736.84
Details
Ratte 0.094 ng/mL 0.156-10 ng/mL Typical standard curve 96 Tests Anmelden zum Anzeigen 12 bis 14 Tage
$638.00
Details

Weitere ELISA Kits für DNMT3A Interaktionspartner

Pig (Porcine) DNA (Cytosine-5-)-Methyltransferase 3 alpha (DNMT3A) Interaktionspartner

  1. Study demonstrated that overexpression of DNMT3A promoted the expression of cell proliferation markers but significantly decreased the expression of p21 to repress cell proliferation by the methylation of p21 promoter. Moreover, overexpression of DNMT3A decreased lipid accumulation and significantly down-regulated the levels of adipogenic marker genes through the methylation of PPARg promoter.

  2. Data show that the expression levels of the 5 epigenetic modifying genes Dnmt1, Dnmt3a, Hdac1, Kdm3a and Uhrf1 were higher in group pig in highland (TH) than in group Yorkshire in highland (YH).

Cow (Bovine) DNA (Cytosine-5-)-Methyltransferase 3 alpha (DNMT3A) Interaktionspartner

  1. The effect of p53 expression on the development of cloned embryos, and its interaction with HDAC1 and DNMT3A are reported.

  2. The expression levels of DNMT3a and DNMT3b were associated with several beef quality traits.

Horse (Equine) DNA (Cytosine-5-)-Methyltransferase 3 alpha (DNMT3A) Interaktionspartner

  1. Among 18 genotypes analyzed, we were unable to record any significant differences in 5-methyl-2'-deoxycytidine levels, which suggested that age-related changes in global DNA methylation content are rather a function of time, and not a genetic component.

Human DNA (Cytosine-5-)-Methyltransferase 3 alpha (DNMT3A) Interaktionspartner

  1. The data indicate that the localization and activity of DNMT3A are under the combined control of MeCP2 and H3 tail modifications where, depending on the modification status of the H3 tail at the binding sites, MeCP2 can act as either a repressor or activator of DNA methylation.

  2. DNMT3A mRNA was negatively correlated with serum 25(OH)D and positively correlated with VDR DNA methylation in colorectal cancer.

  3. An association was found between DNMT3A mutations and epileptic encephalopathy susceptibility.

  4. Our findings suggest that DNMT3A may be a susceptibility gene for paragangliomas and, if confirmed in future studies, would represent the first example of gain-of-function mutations affecting a DNA methyltransferase gene involved in cancer predisposition.

  5. review recent studies on acute myeloid leukemia with a focus on the clinical features and functional roles of DNMT3A mutations, and discuss future challenges to effectively cure DNMT3A mutation-associated hematopoietic disorders[review]

  6. prognostic impact of DNMT3A R882 mutations at diagnosis among mainly older (>60 years) AML patients who underwent non-myeloablative -HSCT.

  7. data indicates that DNMT3AR882H quantification is an unreliable tool for MRD monitoring since it does not reflect disease status in AML, and may rather represent the CHIP substrate.

  8. DNMT3A/3B expression increases progressively from EEC to NEEC and is correlated with poor survival. The mechanisms underlying low ER/PR expression might be distinct in EEC vs. NEEC. In EEC, methylation related to DNMT3A/3B overexpression might play a major role in ER/PR downregulation.

  9. The interaction of the DNMT3A PWWP domain with H3K36me2 and H3K36me3 normally limits DNA methylation.

  10. Distinct clinical and biological implications of various DNMT3A mutations in myeloid neoplasms.

  11. Blastic plasmacytoid dendritic cell neoplasm with unusual morphology, MYC rearrangement and TET2 and DNMT3A mutations.

  12. In this study, we found that DNMT3AR882-associated hypomethylation was preserved in patient-derived AML xenografts with DNMT3AR882, which displayed the same global and focal hypomethylation phenotypes as primary patient samples.

  13. The progress of arterial calcification is regulated by the miR-204/DNMT3a regulatory circuit.

  14. DNMT3A mutation predicts unfavorable outcomes in myelodysplastic syndrome and was stable during disease evolutions. It may thus be a potential biomarker to predict prognosis.

  15. AML patients with FLT3-ITD and DNMT3A R882 double mutations had a very high cumulative recurrence rate and low overall survival, leukocyte-free survival after transplantation

  16. Targeting the DNMT3Ab/Snail/E-cadherin axis may provide a promising therapeutic strategy in the treatment of metastatic GC with high DNMT3Ab expression.

  17. both DNMT3A-WT and R882H/C mutants interacted with PRDX2; and R882C/H mutation-induced hypomethylation increased PRDX2 expression which enhanced cell proliferation and growth with impairment of apoptosis, thereby contributing to leukemogenesis.

  18. In the absence of a concomitant DNA methyltransferase 3A (DNMT3A) mutation, there was no significant difference in overall survival between fms-like tyrosine kinase 3A tandem repeat (FLT3-ITD) positive and FLT3-ITD negative patients.

  19. mutations in the epigenetic regulators TET2 and DNMT3A corresponded to high ARG1 expression and activity. These findings suggest ARG1 is a biomarker of immune dysregulation in early MDS and CMML

  20. results show DNMT3 mutations as additional somatic events in breast implant associated anaplastic large cell lymphoma.

Mouse (Murine) DNA (Cytosine-5-)-Methyltransferase 3 alpha (DNMT3A) Interaktionspartner

  1. The data indicate that the localization and activity of DNMT3A are under the combined control of MeCP2 and H3 tail modifications where, depending on the modification status of the H3 tail at the binding sites, MeCP2 can act as either a repressor or activator of DNA methylation.

  2. Study of mice carrying a point mutation (Dnmt3aD329A) in the DNMT3A-PWWP domain, revealed that it is gain of function mutation and results in progressive DNA hypermethylation across domains marked by H3K27me3 and bivalent chromatin and de-repression of developmental regulatory genes in adult hypothalamus that manifests phenotypically as dominant postnatal growth retardation.

  3. The results of this study identify Dnmt3a2 as an important epigenetic regulator needed for the establishment of central sensitization. Targeting expression or function of Dnmt3a2 may be suitable for the treatment of chronic pain.

  4. SUV39H1/DNMT3A-dependent methylation of the RB1 promoter stimulates PIN1 expression and melanoma development.

  5. The progress of arterial calcification is regulated by the miR-204/DNMT3a regulatory circuit.

  6. Deletion of the de novo DNA methyltransferases Dnmt3a and Dnmt3b in mouse B cells results in normal B cell development and maturation, but increased cell activation and expansion of the germinal center B cell and plasma cell populations upon immunization.

  7. the upregulation of DNMT3A emerges as a prominent molecular event triggered by ethanol, driven by the generation of reactive oxygen species.

  8. Dnmt3a appears to regulate satellite cell differentiation via DNA methylation. This mechanism may play a role in the decreased regeneration capacity during atrophy such as in aged sarcopenia.

  9. DNMT3A and TET1 regulate the epigenome and gene expression at specific targets via their functional interplay.

  10. individual pain vulnerability may be inherent mostly in the emotional/affective component of chronic pain and remain consistent in different aspects of negative emotion, in which adaptive changes in the function of DNA methyltransferase 3a for DNA methylation in central amygdala may play an important role.

  11. Taken together, these data demonstrate that adipose Dnmt3a is a novel epigenetic mediator of insulin resistance in vitro and in vivo.

  12. The aim of the present study is to investigate spatial and temporal expression levels and subcellular localizations of the DNMT1, DNMT3A, and DNMT3B proteins in the mouse germinal vesicle (GV) and metaphase II (MII) oocytes, and early embryos from 1-cell to blastocyst stages.

  13. our Dnmt3a R878H mice have shown that leukemic cells have altered gene expression and epigenetic regulatory patterns contributing to the growth/survival advantage over WT mice.The present study found that the DNMT3A mutation contributed to hypomethylation in the gene body region of mTOR in Dnmt3aR878H/WT mice.

  14. Knockdown of DNMT3A or DNMT1 protected neurons against mutant Htt-induced toxicity, together demonstrating a requirement for DNMTs in mutant Htt-triggered neuronal death and suggesting a neurodegenerative mechanism based on DNA methylation-mediated transcriptional repression.

  15. Data demonstrate that DNMT3A and DNA methylation are key modulators of mast cell responsiveness to acute and chronic stimulation.

  16. These data suggest that DNMT3a is required for nerve injury-induced and MBD1-mediated epigenetic silencing of the MOR and KOR in the injured DRG. DNMT3a inhibition may serve as a promising adjuvant therapy for opioid use in neuropathic pain management.

  17. Data show that conditional deletion of Dnmt3a and simultaneous "knock in" of Flt3ITD/+, cooperate to drive leukemia development at a faster rate than Dnmt3a loss alone.

  18. Deletion of DNMT3a in postnatal forebrain neurons does no alter affective behavior.

  19. Altogether, the authors demonstrate that Dnmt3a and Dnmt3b protect the epidermis from tumorigenesis and that squamous carcinomas are sensitive to inhibition of PPAR-gamma.

  20. Upon lysolecithin injection in the spinal cord of transgenic mice, study detected defective oligodendrocyte progenitor cells differentiation and inefficient remyelination in the DNA methyltransferase 3a null and DNA methyltransferase 1/DNA methyltransferase 3a null mice.

DNMT3A Antigen-Profil

Beschreibung des Gens

CpG methylation is an epigenetic modification that is important for embryonic development, imprinting, and X-chromosome inactivation. Studies in mice have demonstrated that DNA methylation is required for mammalian development. This gene encodes a DNA methyltransferase that is thought to function in de novo methylation, rather than maintenance methylation. The protein localizes to the cytoplasm and nucleus and its expression is developmentally regulated. Alternative splicing results in multiple transcript variants encoding different isoforms.

Genbezeichner und Symbole assoziert mit DNMT3A

  • DNA methyltransferase 3 alpha (DNMT3A) Antikörper
  • DNA methyltransferase 3A (Dnmt3a) Antikörper
  • DNA methyltransferase 3 alpha (Dnmt3a) Antikörper
  • DNA methyltransferase 3 alpha (dnmt3a) Antikörper
  • DNA (cytosine-5-)-methyltransferase 3 alpha b (dnmt3ab) Antikörper
  • DNMT3A Antikörper
  • dnmt3a1 Antikörper
  • DNMT3A2 Antikörper
  • dnmt6 Antikörper
  • M.HsaIIIA Antikörper
  • MmuIIIA Antikörper

Bezeichner auf Proteinebene für DNMT3A

DNA (cytosine-5)-methyltransferase 3A , DNA cytosine methyltransferase 3 alpha , DNA (cytosine-5-)-methyltransferase 3 alpha , DNA MTase HsaIIIA , DNA cytosine methyltransferase 3A2 , DNA methyltransferase 3A , DNA methyl transferase alpha , DNA-methyltransferase 3a , DNA MTase MmuIIIA , DNA methyltransferase MmuIIIA , LOW QUALITY PROTEIN: DNA (cytosine-5)-methyltransferase 3A , DNA (cytosine-5-)-methyltransferase 6

GENE ID SPEZIES
100037301 Sus scrofa
359716 Bos taurus
739139 Pan troglodytes
694822 Macaca mulatta
100055881 Equus caballus
482996 Canis lupus familiaris
1788 Homo sapiens
421991 Gallus gallus
100030681 Monodelphis domestica
100344715 Oryctolagus cuniculus
100500776 Ovis aries
100510798 Felis catus
100594618 Nomascus leucogenys
13435 Mus musculus
444984 Rattus norvegicus
100529107 Anolis carolinensis
100721625 Cavia porcellus
553189 Danio rerio
Ausgewählte Anbieter für DNMT3A (DNMT3A) ELISA Kits
Haben Sie etwas anderes gesucht?